Novo Nordisk and OpenAI announced a strategic partnership on April 14, 2026. It covers the use of OpenAI's models from drug discovery through manufacturing, supply chain and commercial operations, starting with pilot programmes, with full integration expected by the end of 2026. The companies gave no financial terms, no contract length and no model names. In September 2026 Novo Nordisk added a separate agreement with Anthropic. As of November 13, 2026, we found no company update on whether the integration target has been met.
Key Dates
| Date | Event |
|---|---|
| April 14, 2026 | Novo Nordisk and OpenAI announce the partnership from Bagsværd, Denmark |
| April 16, 2026 | OpenAI introduces GPT-Rosalind, a life-sciences model. Press coverage lists Novo Nordisk among the organisations working with it |
| September 11, 2026 | OpenAI says GPT-Rosalind is leaving research preview |
| September 16, 2026 | Novo Nordisk announces a collaboration with Anthropic. Euronews reports the company is already using GPT-Rosalind |
| End of 2026 | Target for full integration of OpenAI's technology, as stated in April |
What Was Disclosed and What Was Not
| Item | Status | Detail |
|---|---|---|
| Scope | Disclosed | Analysing complex datasets, identifying drug candidates, and shortening the time from research to patients. Also manufacturing, supply chain, distribution and corporate operations |
| Rollout | Disclosed | Pilots in research and development, manufacturing and commercial operations. Full integration by the end of 2026 |
| Training | Disclosed | OpenAI will help raise AI skills across Novo Nordisk's global workforce |
| Governance | Disclosed in general terms | The release refers to strict data protection, governance and human oversight |
| Financial terms | Not disclosed | |
| Contract length | Not disclosed | |
| Models used | Not named in the release | Later coverage says the company uses GPT-Rosalind |
| Exclusivity | Not stated | The release says the deal builds on existing AI work with other technology partners |
| Specific drug programmes | Not disclosed | |
| What data OpenAI can access | Not disclosed |
This is a technology agreement. No molecule is licensed and there are no milestone payments, which sets it apart from most entries in the AI pharma deal tracker.
What the Executives Said
In the release, Novo Nordisk chief executive Mike Doustdar said AI lets the company analyse datasets at a scale that was "previously impossible". OpenAI chief executive Sam Altman said AI in life sciences "can help people live better, longer lives".
The Anthropic Agreement
On September 16, 2026, Novo Nordisk said it would also use Anthropic's Claude models in R&D and test Claude Science, according to Euronews. Terms were not disclosed. The report presents it as part of a wider investment in AI and does not say whether the two agreements overlap. More on the Anthropic life sciences partnerships page.
OpenAI's Other Life-Science Work
| Item | Date | What it is |
|---|---|---|
| GPT-Rosalind | April 16, 2026 | A reasoning model for biology, drug discovery and translational medicine. First offered as a research preview to qualified enterprise customers in the United States through a trusted-access programme |
| Life sciences plugin for Codex | April 2026 | A free plugin connecting to more than 50 public databases and tools, including AlphaFold and BindingDB |
| GPT-Rosalind leaves preview | September 11, 2026 | Available to eligible organisations worldwide, still through trusted access. Third-party trackers list API pricing of $5 per million input tokens and $25 per million output tokens from October 5, 2026 |
| Named GPT-Rosalind organisations | April 2026 | Amgen, Moderna, Thermo Fisher Scientific, Novo Nordisk, the Allen Institute and the UCSF School of Pharmacy, among others, per launch coverage |
| Thermo Fisher Scientific | October 2025 | A collaboration on drug development, per R&D World |
| Retro Biosciences | 2025 | A small protein-engineering model, GPT-4b micro, built with Retro |
| Eli Lilly | June 2024 | A collaboration on antimicrobials for drug-resistant bacteria, per BioSpace |
OpenAI has not announced drug programmes of its own. How GPT-Rosalind compares with the other frontier-lab efforts is at Claude Science vs GPT-Rosalind vs Isomorphic Labs.
Methodology
Partnership facts come from the Novo Nordisk company release of April 14, 2026, read on Inderes. GPT-Rosalind details come from The Decoder and eWeek, because OpenAI's own announcement page blocked our reader. The September update and pricing come from AI Catchup, a secondary source. The Anthropic agreement is from Euronews. Status as of November 13, 2026.